UNASSIGNED: The house dust mite is one of the most common allergens worldwide. There is good evidence that house dust mite subcutaneous immunotherapy is efficacious and has long-term benefit in @entity1 . However, the evidence of the benefit of house dust mite @entity13366 ( @entity13366 ) is less convincing. The purpose of this meta-analysis was to evaluate that efficacy and safety of dust mite @entity13366 in @entity1 with @entity565 .Medical Literature Analysis and Retrieval System Online, ISI Web of Knowledge, and Cochrane Central Register of Controlled Trials databases until February 2014 were searched. The primary outcome was mean change in @entity565 symptom score. Secondary outcomes included mean change in serum immunoglobulin G4 (sIgG4), specific @entity7130 , immunoglobulin E (IgE) levels, and medication score. Safety was also assessed.We found that @entity13366 significantly decreased @entity565 symptom score (P=0.007) and increased sIgG4 levels (P=0.011) greater than control in @entity1 (<18 years of age) with @entity565 . There was no difference between @entity13366 and control groups in specific @entity7130 IgE levels (P=0.076) and medication score (P=0.408). The safety profile was similar between groups.Our study indicates that dust mite @entity13366 therapy was effective in reducing @entity565 symptoms and in increasing sIgG4 but did not significantly reduce medication scores or specific @entity7130 IgE levels. Our findings are not enough to support the use of dust mite @entity13366 in @entity1 with @entity565 .

Sublingual Immunotherapy for Asthmatic XXXX Sensitized to House Dust Mite: A Meta-Analysis.

@entity1 :: ('9606', 'Species') :: ['children'] @entity565 :: ('MESH:D001249', 'Disease') :: ['asthma'] @entity13366 :: ('MESH:D013362', 'Disease') :: ['SLIT', 'sublingual immunotherapy'] @entity7130 :: ('6956', 'Species') :: ['Dermatophagoides pteronyssinus', 'D pteronyssinus']
@entity1 :: (9606,Species) :: ['Children']
